Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash from Investing Activities: 2022-2025

Historic Cash from Investing Activities for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $50.4 million.

  • Praxis Precision Medicines' Cash from Investing Activities rose 1.71% to $50.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 102.66%. This contributed to the annual value of -$248.5 million for FY2024, which is 737.98% down from last year.
  • Per Praxis Precision Medicines' latest filing, its Cash from Investing Activities stood at $50.4 million for Q3 2025, which was up 181.73% from $17.9 million recorded in Q2 2025.
  • Praxis Precision Medicines' 5-year Cash from Investing Activities high stood at $50.4 million for Q3 2025, and its period low was -$195.9 million during Q2 2024.
  • Its 3-year average for Cash from Investing Activities is -$19.2 million, with a median of $2.5 million in 2023.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first spiked by 497.66% in 2023, then crashed by 21,736.00% in 2024.
  • Quarterly analysis of 4 years shows Praxis Precision Medicines' Cash from Investing Activities stood at $22.6 million in 2022, then plummeted by 100.22% to -$50,000 in 2023, then plummeted by 21,736.00% to -$10.9 million in 2024, then rose by 1.71% to $50.4 million in 2025.
  • Its last three reported values are $50.4 million in Q3 2025, $17.9 million for Q2 2025, and -$51.1 million during Q1 2025.